Literature DB >> 15118010

Time to stop progesterone receptor testing in breast cancer management.

Ivo A Olivotto, Pauline T Truong, Caroline H Speers, Vanessa Bernstein, Sharon J Allan, Seamus J Kelly, Mary L Lesperance.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15118010     DOI： 10.1200/JCO.2004.99.251

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  24 in total

1.  Single hormone receptor-positive breast cancer patients experienced poor survival outcomes: a systematic review and meta-analysis.

Authors:  N Wu; F Fu; L Chen; Y Lin; P Yang; C Wang
Journal:  Clin Transl Oncol       Date:  2019-06-20       Impact factor: 3.405

2.  Clinical significance of progesterone receptor and HER2 status in estrogen receptor-positive, operable breast cancer with adjuvant tamoxifen.

Authors:  Yong Wha Moon; Seho Park; Joo Hyuk Sohn; Dae Ryong Kang; Ja Seung Koo; Hyung Seok Park; Hyun Cheol Chung; Byeong-Woo Park
Journal:  J Cancer Res Clin Oncol       Date:  2011-02-16       Impact factor: 4.553

3.  Association between tumour characteristics and HER-2/neu by immunohistochemistry in 1362 women with primary operable breast cancer.

Authors:  H J Huang; P Neven; M Drijkoningen; R Paridaens; H Wildiers; E Van Limbergen; P Berteloot; F Amant; I Vergote; M R Christiaens
Journal:  J Clin Pathol       Date:  2005-06       Impact factor: 3.411

4.  A network-based pharmacological study on the mechanism of action of muscone in breast cancer.

Authors:  Yurong Zhao; Shuaixian Tao; Qiang Wang; Yan Liu; Wenke Yang; Shoude Zhang; Zhanhai Su; Xueman Ma
Journal:  Transl Cancer Res       Date:  2022-05       Impact factor: 0.496

5.  Heterogeneity in the expression of receptors in the human breast cancer metastasized to the brain.

Authors:  Prema S Rao; Morgan Labhart; Susan L Mayhew; Seshadri Thirumala; U Subrahmanyeswara Rao
Journal:  Tumour Biol       Date:  2014-04-29

6.  Evaluation of three commercial progesterone receptor assays in a single tamoxifen-treated breast cancer cohort.

Authors:  Elizabeth N Kornaga; Alexander C Klimowicz; Natalia Guggisberg; Travis Ogilvie; Don G Morris; Marc Webster; Anthony M Magliocco
Journal:  Mod Pathol       Date:  2016-08-26       Impact factor: 7.842

7.  The impact of progesterone receptor negativity on oncological outcomes in oestrogen-receptor-positive breast cancer.

Authors:  M G Davey; É J Ryan; P J Folan; N O'Halloran; M R Boland; M K Barry; K J Sweeney; C M Malone; R J McLaughlin; M J Kerin; A J Lowery
Journal:  BJS Open       Date:  2021-05-07

8.  Hormone-receptor expression and survival patterns in operated cases of female invasive ductal breast carcinoma in Kerala: a retrospective cohort study.

Authors:  Ajith Vettuparambil; Ravindran Chirukandath; Terence B Culas; Sajna Mathumkunnath Vijayan; Gautham Rajan; Sathidevi Vadakkepura Kuttappan
Journal:  World J Surg Oncol       Date:  2015-04-23       Impact factor: 2.754

9.  Survival benefit of tamoxifen in estrogen receptor-negative and progesterone receptor-positive low grade breast cancer patients.

Authors:  Li-Heng Yang; Hsin-Shun Tseng; Che Lin; Li-Sheng Chen; Shou-Tung Chen; Shou-Jen Kuo; Dar-Ren Chen
Journal:  J Breast Cancer       Date:  2012-09-28       Impact factor: 3.588

10.  Prognostic Significance of Single Progesterone Receptor Positivity: A Comparison Study of Estrogen Receptor Negative/Progesterone Receptor Positive/Her2 Negative Primary Breast Cancer With Triple Negative Breast Cancer.

Authors:  Ying Fan; Xiaoyan Ding; Binghe Xu; Fei Ma; Peng Yuan; Jiayu Wang; Pin Zhang; Qing Li; Yang Luo
Journal:  Medicine (Baltimore)       Date:  2015-11       Impact factor: 1.817
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.